Drug Trial Radar · NCT05123482
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Oct 18, 2021
Primary completion
Sep 29, 2027
Study completion Sep 29, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Conditions
- Breast Cancer
- Biliary Tract Carcinoma
- Ovarian Cancer
- Endometrial Cancer
- Squamous Non-Small Cell Lung Cancer
Interventions
AZD8205Drug
AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.
AZD8205 and AZD2936 (Rilvegostomig)Drug
AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
AZD8205 and AZD5305 (saruparib)Drug
AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)Drug
AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
AZD8205 in combination with AZD9574Drug
AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)Drug
AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of patients with adverse eventsTime frame: From time of Informed consent to 30 days post last dose (approximately 1 year).
- The number of patients with serious adverse eventsTime frame: From time of Informed consent to 30 days post last dose (approximately 1 year)
- The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: From first dose of study treatment until the end of Cycle 1 (approximately 21 days).
- The number of patients with changes from baseline laboratory findings, ECGs and vital signsTime frame: From time of informed consent to 30 days post last dose (approximately 1 year)
Locations
67 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Completed
Research Site
Irvine, California · Completed
Research Site
Santa Monica, California · Recruiting
Research Site
Santa Rosa, California · Recruiting
Research Site
Shreveport, Louisiana · Completed
Research Site
Baltimore, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Albuquerque, New Mexico · Recruiting
Research Site
Commack, New York · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Clayton, Australia · Terminated
Research Site
Melbourne, Australia · Recruiting
Research Site
Nedlands, Australia · Active not recruiting
Research Site
Anderlecht, Belgium · Recruiting
Research Site
Leuven, Belgium · Recruiting
Research Site
Calgary, Alberta, Canada · Recruiting
Research Site
Vancouver, British Columbia, Canada · Recruiting
Research Site
Ottawa, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Completed
Research Site
Beijing, China · Completed
Research Site
Beijing, China · Recruiting
Research Site
Changsha, China · Terminated
Research Site
Changsha, China · Recruiting
Research Site
Chongqing, China · Recruiting
Research Site
Guangzhou, China · Completed
Research Site
Kunming, China · Recruiting
Research Site
Shandong, China · Recruiting
Research Site
Budapest, Hungary · Withdrawn
Research Site
Budapest, Hungary · Recruiting
Research Site
Budapest, Hungary · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Modena, Italy · Recruiting
Research Site
Roma, Italy · Recruiting
Research Site
Chūōku, Japan · Recruiting
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.